Further evidence for low-dose combinations in patients with left ventricular hypertrophy

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular disease.
• Reversal of LVH is a key objective in managing hypertension.
• Low-dose combination therapy is increasingly recognized for its benefits in hypertension management.

Purpose of the Study:

• To evaluate the efficacy of a low-dose combination therapy (perindopril/indapamide) versus monotherapy in reducing left ventricular mass in hypertensive patients.
• To compare the effects of combination therapy and monotherapy on central and peripheral blood pressure and pulse pressure.

Main Methods:

• The REASON study compared a low-dose ACE inhibitor/diuretic combination with beta-blocker monotherapy.
• The PICXEL study compared the same low-dose combination with ACE inhibitor monotherapy.
• Both studies included hypertensive patients with LVH and assessed changes in left ventricular mass and blood pressure over 1 year.

Main Results:

• The low-dose combination therapy resulted in a significantly greater reduction in left ventricular mass compared to beta-blocker monotherapy in the REASON study.
• Perindopril/indapamide demonstrated superior reduction in central and peripheral systolic blood pressure and pulse pressure compared to beta-blocker.
• The PICXEL study also showed significantly greater decreases in LVH parameters and blood pressure with the low-dose combination therapy over 1 year.

Conclusions:

• Low-dose combination therapy, specifically perindopril/indapamide, is more effective in reversing left ventricular hypertrophy than traditional monotherapies.
• The benefits of this combination therapy extend beyond blood pressure reduction, impacting central hemodynamic changes crucial for LVH regression.
• This strategy represents a significant advancement in antihypertensive management for patients with LVH.